date: 2015-06-03 18:00:00 click:
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of consulting services and software
for pharmaceutical discovery and development, today announced that it has signed a distributor agreement with the Research Institute
for Liver Diseases (RILD) in Shanghai, People’s Republic of China.
Mr. John DiBella, vice president for marketing and sales for Simulations Plus, said, “Were very pleased to be working with the RILD
to offer in silico consulting services using our various software programs in support of RILD in vitro experimental systems to its
customers in China. Dr. Zhuohan Hu, President and CEO of RILD, is highly respected within industry in China, and we look forward to
leveraging his connections with researchers at regulatory agencies and local companies to continue penetrating this growing market.
We expect this new dealership to help promote our consulting services in the areas of drug absorption, toxicity, metabolism, and drug-drug interactions.”
About Simulations Plus, Inc.
Simulations Plus, Inc., is a premier developer of groundbreaking drug discovery and development simulation and modeling software,
which is licensed to and used in the conduct of drug research by major pharmaceutical, biotechnology, agrochemical, and food industry
companies worldwide. Simulations Plus, Inc., is headquartered in Southern California and trades on the NASDAQ Capital Market
under the symbol “SLP.” For more information, visit our Web site at www.simulations-plus.com.